Kidder Stephen W decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 19,649 shares of the biopharmaceutical company’s stock after selling 898 shares during the period. Kidder Stephen W’s holdings in Gilead Sciences were worth $1,391,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of GILD. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. boosted its stake in shares of Gilead Sciences by 19.4% during the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 267 shares during the last quarter. Penserra Capital Management LLC boosted its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares during the last quarter. Webster Bank N. A. boosted its stake in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 624 shares during the last quarter. Finally, American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter valued at $143,000. 73.97% of the stock is currently owned by institutional investors.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,819 shares of company stock worth $36,740,240. Insiders own 1.30% of the company’s stock.
A number of brokerages have issued reports on GILD. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target on the stock in a research note on Wednesday, September 6th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, July 27th. ValuEngine lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $82.00 price objective (up from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Eleven investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.29.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Cut by Kidder Stephen W” was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-stake-decreased-by-kidder-stephen-w/1603640.html.
Shares of Gilead Sciences, Inc. (GILD) opened at 83.27 on Friday. The stock has a 50 day moving average price of $77.54 and a 200 day moving average price of $70.38. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The firm has a market cap of $108.74 billion, a PE ratio of 9.04 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period last year, the firm posted $3.08 earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.78 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. Gilead Sciences’s payout ratio is presently 22.58%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.